The global weight-loss drug market, once dominated by Novo Nordisk, is undergoing a dramatic transformation. On Friday, the ...

Eli Lilly and Co's obesity drug Zepbound led to greater weight loss than Novo Nordisk's Wegovy in a head-to-head Phase 3b ...

Zepbound outperformed Nordisk's Wegovy in terms of weight loss, solidifying Lilly's leadership in the anti-obesity drug ...

Novo Nordisk’s new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and ...

The obesity drug helped patients reduce their waist size by an extra two inches compared to those on Novo Nordisk’s Wegovy in ...

Tirzepatide (Zepbound) led to more weight loss than semaglutide (Wegovy) in a clinical trial funded by Eli Lilly.

This trial consisted of 751 people in the U.S. who were overweight or had obesity and roughly one other weight-related health ...

Eli Lilly’s obesity drug Zepbound led to nearly 50 percent more weight loss than Novo Nordisk’s Wegovy in the first direct ...

President Trump said he would sign an executive order to base U.S. drug prices on what other countries pay — usually far less ...

May 12 (Reuters) - Eli Lilly (LLY.N), opens new tab said on Sunday its drug Zepbound ... in the head-to-head trial was lower than in a 2021 trial with similar dose. "Obesity is about more than ...

Eli Lilly's Zepbound surpassed Novo Nordisk's Wegovy in reducing waist circumference and overall weight loss in a recent ...

A new study shows that people Zepbound lost about 50% more weight than those using Wegovy. It was the first head-to-head ...